Bert Vogelstein awarded Warren Triennial Prize by assachusetts General Hospital

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BERT VOGELSTEIN was awarded the 2014 Warren Triennial Prize by Massachusetts General Hospital.

Vogelstein is the Clayton Professor of Oncology and Pathology and director of the Ludwig Center for Cancer Genetics and Therapeutics at Johns Hopkins University School of Medicine. The award will be presented at the Warren Triennial Prize Symposium, “The Genetics of Cancer,” on Nov. 24 at MGH.

Vogelstein and his colleagues demonstrated that colorectal tumors result from the gradual accumulation of alterations in specific oncogenes and tumor suppressor genes, with major implications for improved diagnostic and therapeutic strategies.

He and his colleagues were also the first to map cancer genomes and to use genome-wide sequencing to identify the basis of a hereditary disease. His team has determined the genetic landscapes of more than a dozen tumor types.

The Warren Prize is the top scientific award presented by MGH, and includes a cash award of $50,000. Created in 1871, the prize was named for John Collins Warren, a co-founder of the MGH who played a leading role in establishing what became the New England Journal of Medicine, and also performed the first public surgical operation utilizing ether anesthesia in 1846.

Twenty-three Warren recipients have also received the Nobel Prize–including 2011 recipient Shinya Yamanaka, a 2012 Nobel laureate; and 2004 recipients Craig Mello and Andrew Fire, who received the 2006 Nobel.

YOU MAY BE INTERESTED IN

By the end of 2022, Toni Monteiro had no fight left in her. She had been battling a rare blood cancer for three years. Her husband had just died. She was at risk of being evicted from her Washington, DC, apartment. Also, her heart was failing. “You’re really under stress,” Monteiro recalls her physician saying. ...

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.

Login